{"disease":{"id":"malignant-solid-tumor","name":"malignant solid tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05594147","title":"An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib","phase":"","overall_status":"COMPLETED","enrollment_count":4103,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06702566","title":"The Effect of Serum Ferritin in irAE","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07307053","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04495790","title":"AIMS Cancer Outcomes Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Advanced Integrative Medical Science Institute","has_results":false},{"nct_id":"NCT07480733","title":"Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":480,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT03905720","title":"Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services","phase":"NA","overall_status":"COMPLETED","enrollment_count":448,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03222258","title":"Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT07287995","title":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT00003816","title":"Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT06115642","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT05245500","title":"Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04225117","title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":329,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT02601950","title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT06464055","title":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04145622","title":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT07391644","title":"A Study of JSKN027 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT02754141","title":"An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07292402","title":"JSKN022 in Subjects With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT02091999","title":"A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04632108","title":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":199,"lead_sponsor_name":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06810544","title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":191,"lead_sponsor_name":"Tango Therapeutics, Inc.","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05094804","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT06090266","title":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT03192345","title":"A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07459920","title":"Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"National Cancer Institute, Naples","has_results":false},{"nct_id":"NCT07436728","title":"A Study of TAK-505 in Adults With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":151,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06154343","title":"A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07293754","title":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Repertoire Immune Medicines","has_results":false},{"nct_id":"NCT05495295","title":"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":149,"lead_sponsor_name":"Phost'In Therapeutics","has_results":false},{"nct_id":"NCT06788886","title":"Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06592417","title":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Neonc Technologies, Inc.","has_results":false},{"nct_id":"NCT07124195","title":"Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"The First Affiliated Hospital of Xinxiang Medical College","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05103358","title":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Aadi Bioscience, Inc.","has_results":false},{"nct_id":"NCT05396339","title":"A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"SUNHO（China）BioPharmaceutical CO., Ltd.","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05277454","title":"Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":113,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT07368127","title":"A Study of TPD3310 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.","has_results":false},{"nct_id":"NCT07050641","title":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}